All In Biotech

Drug Trial Radar · NCT07795164

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Dec 2028

Study completion Dec 2032

Sponsor

Lead sponsor
Altimmune, Inc.Industry
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Interventions

  • PemvidutideDrug

    Pemvidutide SC Injection

  • PlaceboOther

    Placebo SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Outcome EventTime frame: Baseline through end of study (approximately Month 60)
  2. Histological Response: MASH resolutionTime frame: Baseline through Week 52
  3. Histological Response: Fibrosis improvementTime frame: Baseline through Week 52

Locations

62 sites in 2 countries. Site status is shown where the registry gives one.

  • Altimmune Clinical Study Site

    Dothan, Alabama · Recruiting

  • Altimmune Clinical Study Site

    Chandler, Arizona · Recruiting

  • Altimmune Clinical Study Site

    Tucson, Arizona · Recruiting

  • Altimmune Clinical Study Site

    Little Rock, Arkansas · Recruiting

  • Altimmune Clinical Study Site

    North Little Rock, Arkansas · Recruiting

  • Altimmune Clinical Study Site

    Fountain Valley, California · Recruiting

  • Altimmune Clinical Study Site

    Fresno, California · Recruiting

  • Altimmune Clinical Study Site

    Gardena, California · Recruiting

  • Altimmune Clinical Study Site

    Huntington Park, California · Recruiting

  • Altimmune Clinical Study Site

    La Mesa, California · Recruiting

  • Altimmune Clinical Study Site

    Long Beach, California · Recruiting

  • Altimmune Clinical Study Site

    Orange, California · Recruiting

  • Altimmune Clinical Study Site

    Orange, California · Recruiting

  • Altimmune Clinical Study Site

    Poway, California · Recruiting

  • Altimmune Clinical Study Site

    Van Nuys, California · Recruiting

  • Altimmune Clinical Study Site

    Englewood, Colorado · Recruiting

  • Altimmune Clinical Study Site

    Boca Raton, Florida · Recruiting

  • Altimmune Clinical Study Site

    Bradenton, Florida · Recruiting

  • Altimmune Clinical Study Site

    Miami, Florida · Recruiting

  • Altimmune Clinical Study Site

    Miami, Florida · Recruiting

  • Altimmune Clinical Study Site

    Miami Lakes, Florida · Recruiting

  • Altimmune Clinical Study Site

    Ocala, Florida · Recruiting

  • Altimmune Clinical Study Site

    Orlando, Florida · Recruiting

  • Altimmune Clinical Study Site

    Port Orange, Florida · Recruiting

  • Altimmune Clinical Study Site

    Dalton, Georgia · Recruiting

  • Altimmune Clinical Study Site

    South Bend, Indiana · Recruiting

  • Altimmune Clinical Study Site

    Bastrop, Louisiana · Recruiting

  • Altimmune Clinical Study Site

    Marrero, Louisiana · Recruiting

  • Altimmune Clinical Study Site

    Monroe, Louisiana · Recruiting

  • Altimmune Clinical Study Site

    Laurel, Maryland · Recruiting

  • Altimmune Clinical Study Site

    New Bedford, Massachusetts · Recruiting

  • Altimmune Clinical Study Site

    Columbia, Missouri · Recruiting

  • Altimmune Clinical Study Site

    Kansas City, Missouri · Recruiting

  • Altimmune Clinical Study Site

    Albuquerque, New Mexico · Recruiting

  • Altimmune Clinical Study Site

    Fayetteville, North Carolina · Recruiting

  • Altimmune Clinical Study Site

    Brooklyn, Ohio · Recruiting

  • Altimmune Clinical Study Site

    Springboro, Ohio · Recruiting

  • Altimmune Clinical Study Site

    Westlake, Ohio · Recruiting

  • Altimmune Clinical Study Site

    East Greenwich, Rhode Island · Recruiting

  • Altimmune Clinical Study Site

    Austin, Texas · Recruiting

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.